Celldex re­veals Phase 2 re­spons­es for chron­ic hives drug and high­er rates of neu­trope­nia

Celldex Ther­a­peu­tics has un­veiled 52-week re­sults from a mid-stage study of its an­ti-KIT drug in chron­ic hives, rais­ing an­tic­i­pa­tion for on­go­ing reg­is­tra­tional stud­ies.

But the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER